1. The interplay of KRAS mutational status with tumor laterality in non-metastatic colorectal cancer: An international, multi-institutional study in patients with known KRAS, BRAF, and MSI status
- Author
-
Emmanouil Pikoulis, Anastasia Pikouli, Georgios Antonios Margonis, Katsunori Imai, Neda Amini, Shigenori Kadowaki, Jaeyun Wang, Carsten Kamphues, Maria Theochari, Takahiko Akiyama, Despoina Geka, Jan N. M. IJzermans, Miho Kakuta, George Theodoropoulos, Toshiro Ogura, Nikolaos Andreatos, Efstathios Antoniou, Yuki Sakamoto, Nobuya Daitoku, Stefan Buettner, Kiwamu Akagi, Martin E. Kreis, Inge van den Berg, and Surgery
- Subjects
Male ,Proto-Oncogene Proteins B-raf ,Oncology ,medicine.medical_specialty ,Colorectal cancer ,colorectal cancer ,medicine.disease_cause ,Resection ,Proto-Oncogene Proteins p21(ras) ,03 medical and health sciences ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,Statistical significance ,Internal medicine ,Biomarkers, Tumor ,Humans ,Medicine ,Non metastatic ,Mutational status ,In patient ,metastases ,Aged ,Retrospective Studies ,business.industry ,Liver Neoplasms ,General Medicine ,Middle Aged ,Prognosis ,medicine.disease ,Survival Rate ,030220 oncology & carcinogenesis ,laterality ,Mutation ,Laterality ,Female ,030211 gastroenterology & hepatology ,Surgery ,KRAS ,Neoplasm Recurrence, Local ,Colorectal Neoplasms ,business ,Colorectal Surgery ,600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit ,Follow-Up Studies ,Microsatellite Repeats - Abstract
Background: Although the prognostic relevance of KRAS status in metastatic colorectal cancer (CRC) depends on tumor laterality, this relationship is largely unknown in non-metastatic CRC. Methods: Patients who underwent resection for non-metastatic CRC between 2000 and 2018 were identified from institutional databases at six academic tertiary centers in Europe and Japan. The prognostic relevance of KRAS status in patients with right-sided (RS), left-sided (LS), and rectal cancers was assessed. Results: Of the 1093 eligible patients, 378 had right-sided tumors and 715 had left-sided tumors. Among patients with RS tumors, the 5-year overall (OS) and recurrence-free survival (RFS) for patients with KRASmut versus wild-type tumors was not shown to differ significantly (82.2% vs. 83.2% and 72.1% vs. 76.7%, respectively, all p >.05). Among those with LS tumors, KRAS mutation was associated with shorter 5-year OS and RFS on both the univariable (OS: 79.4% vs. 86.1%, p =.004; RFS: 68.8% vs. 77.3%, p =.005) and multivariable analysis (OS: HR: 1.52, p =.019; RFS: HR: 1.32, p =.05). Conclusions: KRAS mutation status was independently prognostic among patients with LS tumors, but this association failed to reach statistical significance in RS and rectal tumors. These findings confirm reports in metastatic CRC and underline the possible biologic importance of tumor location.
- Published
- 2021
- Full Text
- View/download PDF